Drug intelligence / Profile preview

SUN-907

Development stage: Preclinical
Lead developer: Sundance Biosciences
Modality: Small Molecules
Administration: Oral

Overview

SUN-907 is an orally bioavailable small molecule inhibitor of Tyrosine Kinase 2 (TYK2) being developed by Sundance Biosciences. TYK2 is a member of the Janus kinase (JAK) family that mediates signaling for several key cytokines involved in inflammatory and immune responses, including IL-12, IL-23, and Type I interferons. By selectively targeting TYK2, SUN-907 aims to modulate neuroinflammatory pathways while potentially avoiding the off-target effects associated with broader JAK inhibitors. The program is currently in the IND-enabling stage, with a primary focus on treating neuroinflammatory conditions.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on SUN-907.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUN-907.

Explore the full profile